Tirzepatide vs. Insulin for Type 2 Diabetes: What the Evidence Shows

The Old Standard vs. The New Option

Insulin has been the backbone of advanced type 2 diabetes management for decades. When oral medications fail to keep blood sugar in range, insulin has traditionally been next. But tirzepatide — the GIP/GLP-1 dual agonist marketed as Mounjaro for diabetes and Zepbound for obesity — is challenging this hierarchy with head-to-head trial data that's difficult to ignore.

What the SURPASS-3 Trial Found

The SURPASS-3 trial directly compared tirzepatide (5mg, 10mg, and 15mg weekly) to insulin degludec (a long-acting basal insulin) in adults with type 2 diabetes inadequately controlled on oral medications.

Key results at 52 weeks: - HbA1c reduction: Tirzepatide 5mg: -1.93%, 10mg: -2.20%, 15mg: -2.37% vs. insulin degludec: -1.34% - Patients achieving HbA1c <7%: 82-93% of tirzepatide patients vs. 61% of insulin patients - Weight: Tirzepatide 5mg: -7.5 kg, 10mg: -10.7 kg, 15mg: -12.9 kg vs. insulin: +2.3 kg - Hypoglycemia: Significantly less frequent in tirzepatide groups

On every clinically meaningful endpoint — glycemic control, weight, hypoglycemia — tirzepatide outperformed basal insulin.

The SURPASS-5 Trial: Adding to Insulin

SURPASS-5 tested tirzepatide added to insulin glargine in patients who needed additional glycemic control beyond basal insulin alone. Tirzepatide addition produced: - Additional -2.11 to -2.59% HbA1c reduction - Weight loss of -5.4 to -8.8 kg (vs. weight gain with placebo insulin intensification) - Reduced insulin dose requirements over time

This is clinically significant: rather than needing more insulin (with all its weight gain and hypoglycemia risks), adding tirzepatide improved control while allowing insulin dose reduction.

Why Insulin Causes Weight Gain

Understanding this asymmetry is important for patients. Insulin is anabolic — it promotes glucose storage as fat, stimulates fat synthesis, and inhibits fat breakdown. Introducing or increasing exogenous insulin in type 2 diabetes: - Drives caloric storage - Increases appetite - Produces a "feed me to avoid hypoglycemia" feedback loop - Can add 3-5 kg within the first year

This weight gain worsens insulin resistance, often requiring progressively higher insulin doses — a trajectory that frustrates patients and physicians alike.

How Tirzepatide Works Differently

Tirzepatide activates two receptors simultaneously: - GLP-1 receptor: Stimulates glucose-dependent insulin secretion (only when blood sugar is high — dramatically reducing hypoglycemia risk), slows gastric emptying, reduces appetite, promotes satiety - GIP receptor: Complements GLP-1 effects on adipose tissue and insulin secretion; GIP may be partly responsible for tirzepatide's weight loss advantages over semaglutide

The result: better glycemic control via glucose-dependent mechanisms (not absolute insulin excess), combined with significant weight loss rather than weight gain.

The Hypoglycemia Difference

Hypoglycemia is the most dangerous acute complication of insulin therapy. Because insulin works regardless of blood glucose level, any miscalculation in dosing, meal timing, or physical activity can push blood sugar too low — with consequences ranging from dizziness and confusion to seizure or loss of consciousness.

Tirzepatide's glucose-dependent mechanism means it stimulates insulin secretion only when blood glucose is actually elevated. When blood sugar is in the normal or low range, the stimulatory effect essentially turns off. This produces dramatically lower rates of clinically significant hypoglycemia.

In SURPASS-3, clinically significant hypoglycemia (blood glucose <54 mg/dL) occurred in 1.7-2.4% of tirzepatide patients vs. 5.4% of insulin patients. For patients who work physical jobs, drive, or live alone, this difference is practically meaningful.

Who This Is Most Relevant For

Patients currently on oral diabetes medications (metformin, SGLT2i) with suboptimal HbA1c: Tirzepatide is now among the most effective options available before insulin ever needs to be considered. The SURPASS trials were largely conducted in patients at this stage.

Patients already on basal insulin: Adding tirzepatide (or switching) should be explicitly discussed, particularly for patients who've gained weight on insulin or who are having hypoglycemic episodes.

Patients considering insulin intensification: Before adding prandial (mealtime) insulin — a significant step in complexity and hypoglycemia risk — adding a GLP-1/GIP agonist is generally the preferable next step.

Obese patients with type 2 diabetes: The combination of superior glycemic control and 15-20% body weight reduction makes tirzepatide uniquely positioned for this population — addressing insulin resistance at its root rather than overcoming it with higher insulin doses.

What Insulin Still Does Better

Insulin isn't obsolete. Specific situations where it remains the appropriate or necessary choice:

• Type 1 diabetes: Tirzepatide does not replace insulin in type 1 — exogenous insulin is essential
• Severely elevated HbA1c with symptomatic hyperglycemia: Rapid insulin titration can quickly bring down dangerously high glucose
• Post-surgical or critically ill patients: Titatble IV insulin remains the standard of care
• Cost: Insulin (particularly generic NPH or glargine biosimilars) can be significantly less expensive than branded tirzepatide for patients without insurance

Accessing Tirzepatide for Type 2 Diabetes

Tirzepatide is FDA-approved as Mounjaro specifically for type 2 diabetes, with demonstrated superiority over basal insulin in multiple trials. Compounded tirzepatide is available through 503B pharmacies as a more affordable alternative to branded Mounjaro.

Marrow prescribes compounded tirzepatide for both type 2 diabetes and weight management based on physician evaluation. The intake process takes five minutes and includes questions about your current diabetes medications, most recent HbA1c, and treatment history.